It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. "TherapeuticsMD's stock is owned by a number of institutional and retail investors. Get short term trading ideas from the MarketBeat Idea Engine. Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. Find real-time TXMD - TherapeuticsMD Inc stock quotes, company profile, news and forecasts from CNN Business. Stock Analysis Report. Wall Street Stock Market & Finance report, prediction for the future: You'll find the TherapeuticsMD share forecasts, stock quote and buy / sell signals below. Media coverage about TXMD stock has been trending very negative this week, InfoTrie reports. Interested parties can register for or listen to the call using TherapeuticsMD Inc (NASDAQ:TXMD) announced its quarterly earnings results on Wednesday, May, 6th.
All rights reserved. Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. TherapeuticsMD had a negative return on equity of 1,170.63% and a negative net margin of 333.88%. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Their forecasts range from $5.00 to $15.00. View analysts' price targets for TherapeuticsMD.
One share of TXMD stock can currently be purchased for approximately $1.85.TherapeuticsMD has a market capitalization of $502.61 million and generates $49.65 million in revenue each year. Their forecasts range from $5.00 to $15.00. TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. High institutional ownership can be a signal of strong market trust in this company.Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.60) to ($0.27) per share.The P/E ratio of TherapeuticsMD is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of TherapeuticsMD is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.TherapeuticsMD has a P/B Ratio of 61.67. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time.
The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. … TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. Top institutional investors include Sanders Morris Harris LLC (1.37%), SG Americas Securities LLC (0.15%), Raymond James Financial Services Advisors Inc. (0.15%), UBS Group AG (0.04%) and Wedbush Securities Inc. (0.01%). The company earned $12.25 million during the quarter, compared to the consensus estimate of $11.48 million. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates.
This suggests a possible upside of 381.0% from the stock's current price. View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat. The company can be reached via phone at 561-961-1900 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Add to Portfolio Compare. TherapeuticsMD, Inc.’s shares saw a change of -39.67% in year-to-date performance and have moved … Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year.
Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 7 analysts have issued 12 month price objectives for TherapeuticsMD's stock.